Home > Nephrology > ASN 2022 > Kidney Transplantation and Dialysis > Wearable serum potassium-monitoring device serves haemodialysis patients well

Wearable serum potassium-monitoring device serves haemodialysis patients well

ASN 2022
A novel proof-of-concept study has shown high sensitivity of the SmartPatch (SP) system, a wearable device to monitor serum potassium levels in haemodialysis patients. Future studies will include patients with hypokalaemia at the start of dialysis, for whom the safety benefit from at-home surveillance is likely greatest, compared with patients in this study who presented with post-dialysis hypokalaemia [1].

Hypo- and hyperkalaemia are serious conditions that can result in extreme adverse outcomes including sudden cardiac death, emphasising the importance of maintaining healthy levels of serum potassium. The SP system, which offers wearable, remote monitoring of serum potassium, was investigated in a study including 96 haemodialysis patients with a functional arteriovenous fistula. During 1 dialysis session per month for 4 months, a wearable SP was applied over the fistula by a nurse or the patient, neither of whom had prior experience placing the device. Hypokalaemia was defined as potassium <3.5 mEq/L and hyperkalaemia was defined as potassium >5.2 mEq/L. In total, 1,229 data recordings were collected. Reference serum potassium values ranged from 2.5 to 6.4 mEq/L (median value 4.2 mEq/L). Reference haematocrit values ranged from 18% to 48% (median value 34%). The SP dyskalaemia algorithm identified dyskalaemia with a total weighted recall of 86%. The precision – also known as the positive predictive value – of the model was 86%, pointing towards both high sensitivity and a low rate of false positives.

  1. Miller F, et al. Wearable Device for Continuous, Non-Invasive Monitoring of Serum Potassium in Hemodialysis Patients. FR-OR43, ASN Kidney Week 2022, 3–6 Nov.


Copyright ©2022 Medicom Medical Publishers

Posted on